• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌少症卡拉特别工作组:临床试验建议

Carla Task Force on Sarcopenia: propositions for clinical trials.

作者信息

Abellan van Kan G, André E, Bischoff Ferrari H A, Boirie Y, Onder G, Pahor M, Ritz P, Rolland Y, Sampaio C, Studenski S, Visser M, Vellas B

机构信息

Gérontopôle, INSERM U558, University of Toulouse III, Toulouse, France.

出版信息

J Nutr Health Aging. 2009 Oct;13(8):700-7. doi: 10.1007/s12603-009-0200-0.

DOI:10.1007/s12603-009-0200-0
PMID:19657553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4311888/
Abstract

In the presence of an aging population, public health priorities need to evolve. As the populations gets older, the already existing pathologies have become commonplace with specific geriatric clinical syndromes like frailty, mobility disability, or cognitive impairment, among others. Sarcopenia is a good example for which geriatricians, neurologists, physiologists, nutritionists and epidemiologists need to find a consensual definition and diagnostic tool as well as guidelines for the management of clinical trials and possible treatments. The Carla Sarcopenia Task Force, which met in the south of France (Toulouse) for an expert consensus meeting called "Les Entretiens du Carla", have addressed a series of existing issues to place Sarcopenia into a nosological context: a definition which should be a composite of a change in muscle mass and a change in strength/function depending on either a progressive and chronic wasting process or an acute onset of loss of muscle mass; a recommendation for DXA and the Short Physical Performance Battery as a clinical pragmatic approach of Sarcopenia; a differentiated approach for clinical studies according to prevention or treatment objectives and depending on the sub-groups and target populations; and finally, a summary of therapeutic strategies currently recommended. The aim of "Les Entretiens du Carla", based on an expert meeting panel, was to address a series of unsolved issues in the field of Sarcopenia by combining the expert opinion with a revision of the existing literature on the topic. Through this report, the reader will appreciate the determination to find conclusions on the various issues and further studies to be developed to determine the best multidisciplinary approach needed.

摘要

在人口老龄化的背景下,公共卫生重点需要与时俱进。随着人口老龄化,诸如衰弱、行动障碍或认知障碍等特定老年临床综合征中已有的病理状况变得司空见惯。肌肉减少症就是一个很好的例子,老年医学专家、神经学家、生理学家、营养学家和流行病学家需要为其找到一个共识性定义、诊断工具以及临床试验管理和可能治疗方法的指南。卡拉肌肉减少症特别工作组在法国南部(图卢兹)召开了一次名为“卡拉研讨会”的专家共识会议,探讨了一系列现有问题,以便将肌肉减少症纳入疾病分类范畴:一个定义,它应综合肌肉质量变化以及取决于渐进性和慢性消瘦过程或肌肉质量急性丧失的力量/功能变化;推荐使用双能X线吸收法(DXA)和简短体能测试电池作为肌肉减少症的临床实用方法;根据预防或治疗目标以及亚组和目标人群对临床研究采取差异化方法;最后,总结目前推荐的治疗策略。基于专家会议小组的“卡拉研讨会”旨在通过将专家意见与对该主题现有文献的修订相结合,解决肌肉减少症领域的一系列未解决问题。通过本报告,读者将体会到为就各种问题得出结论以及开展进一步研究以确定所需最佳多学科方法的决心。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/022d/12275578/c7ce8dddd78a/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/022d/12275578/c7ce8dddd78a/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/022d/12275578/c7ce8dddd78a/fx1.jpg

相似文献

1
Carla Task Force on Sarcopenia: propositions for clinical trials.肌少症卡拉特别工作组:临床试验建议
J Nutr Health Aging. 2009 Oct;13(8):700-7. doi: 10.1007/s12603-009-0200-0.
2
Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR).关于促进老年人健康长寿的最佳运动建议的全球共识(国际功能、健康与老龄化研究学会)
J Nutr Health Aging. 2025 Jan;29(1):100401. doi: 10.1016/j.jnha.2024.100401. Epub 2025 Jan 1.
3
Epidemiology and consequences of sarcopenia.肌肉减少症的流行病学及后果
J Nutr Health Aging. 2009 Oct;13(8):708-12. doi: 10.1007/s12603-009-0201-z.
4
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
5
The effect of Tai Chi in elderly individuals with sarcopenia and frailty: A systematic review and meta-analysis of randomized controlled trials.太极拳对伴有肌少症和衰弱的老年人的影响:系统评价和随机对照试验的荟萃分析。
Ageing Res Rev. 2022 Dec;82:101747. doi: 10.1016/j.arr.2022.101747. Epub 2022 Oct 9.
6
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
7
Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement.关于长新冠患者评估与治疗的多学科协作指南:一份概要声明
PM R. 2025 Apr 22. doi: 10.1002/pmrj.13397.
8
Diet Quality and Sarcopenia in Older Adults: A Systematic Review.老年人饮食质量与肌肉减少症:系统评价。
Nutrients. 2018 Mar 5;10(3):308. doi: 10.3390/nu10030308.
9
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer.针对儿童癌症治疗期间及治疗后的儿童和青少年的体育锻炼训练干预措施。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD008796. doi: 10.1002/14651858.CD008796.pub2.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
The MUnich SArcopenia Registry (MUSAR) : Paving the way for increased visibility, more frequent diagnoses and innovative new treatment.慕尼黑肌少症登记处(MUSAR):为提高认知度、增加诊断频率和创新新疗法铺平道路。
Z Gerontol Geriatr. 2025 May;58(3):197-202. doi: 10.1007/s00391-025-02428-2. Epub 2025 Apr 8.
2
Myosteatosis in Cirrhosis: A Review of Diagnosis, Pathophysiological Mechanisms and Potential Interventions.肝硬化性肌内脂肪变性:诊断、病理生理机制及潜在干预措施的综述。
Cells. 2022 Apr 4;11(7):1216. doi: 10.3390/cells11071216.
3
Selecting Potential Pharmacological Interventions in Sarcopenia.

本文引用的文献

1
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials.补充和活性形式维生素D预防跌倒:随机对照试验的荟萃分析
BMJ. 2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.
2
Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.关于治疗肌肉减少症的药物产品的有效治疗方法和治疗前景。
J Nutr Health Aging. 2009 Oct;13(8):746-56. doi: 10.1007/s12603-009-0209-4.
3
Validated treatments and therapeutic perspectives regarding physical activities.
选择治疗少肌症的潜在药物干预措施。
Drugs Aging. 2017 Apr;34(4):233-240. doi: 10.1007/s40266-017-0444-z.
4
The energy intake through regular nontherapeutic meals provision in long-term care: impact on nutritional status and related Geriatric Nutritional Risk Index.长期护理机构中通过定期提供非治疗性膳食的能量摄入:对营养状况及相关老年营养风险指数的影响
Springerplus. 2016 Feb 20;5:136. doi: 10.1186/s40064-016-1763-y. eCollection 2016.
5
Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older.肌少症现有定义对65岁及以上社区居住老年人跌倒前瞻性发生率的比较表现。
Osteoporos Int. 2015 Dec;26(12):2793-802. doi: 10.1007/s00198-015-3194-y. Epub 2015 Jun 12.
6
Evaluation and Management of the Geriatric Urologic Oncology Patient.老年泌尿肿瘤患者的评估与管理
Curr Geriatr Rep. 2015 Mar;4(1):7-15. doi: 10.1007/s13670-014-0106-5.
7
Vitamin D Deficiency Treatment Patterns in Academic Urban Medical Center.学术性城市医疗中心的维生素D缺乏治疗模式
Am J Pharm Benefits. 2014;6(1):e1-e8.
8
Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.使用国家老龄化研究所肌少症基金会分类标准,对衰弱和低瘦体重老年女性进行分类,并评估其临床干预后的力量和功能反应。
J Gerontol A Biol Sci Med Sci. 2015 Feb;70(2):202-9. doi: 10.1093/gerona/glu110. Epub 2014 Aug 18.
9
The impact of sarcopenia on a physical activity intervention: the Lifestyle Interventions and Independence for Elders Pilot Study (LIFE-P).肌少症对身体活动干预的影响:生活方式干预和老年人独立先导研究 (LIFE-P)。
J Nutr Health Aging. 2014 Jan;18(1):59-64. doi: 10.1007/s12603-013-0369-0.
10
Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).肌肉减少症:生物标志物与影像学(肌肉减少症研究国际会议)
J Nutr Health Aging. 2011 Dec;15(10):834-46. doi: 10.1007/s12603-011-0365-1.
关于体育活动的有效治疗方法和治疗前景。
J Nutr Health Aging. 2009 Oct;13(8):742-5. doi: 10.1007/s12603-009-0208-5.
4
Validated treatments and therapeutic perspectives regarding nutritherapy.关于营养疗法的有效治疗方法和治疗前景。
J Nutr Health Aging. 2009 Oct;13(8):737-41. doi: 10.1007/s12603-009-0207-6.
5
What are the outcomes of treatment among patients with sarcopenia?肌肉减少症患者的治疗结果如何?
J Nutr Health Aging. 2009 Oct;13(8):733-6. doi: 10.1007/s12603-009-0206-7.
6
Target population for clinical trials.临床试验的目标人群。
J Nutr Health Aging. 2009 Oct;13(8):729-32. doi: 10.1007/s12603-009-0205-8.
7
Sarcopenia: clinical evaluation, biological markers and other evaluation tools.肌肉减少症:临床评估、生物标志物及其他评估工具
J Nutr Health Aging. 2009 Oct;13(8):724-8. doi: 10.1007/s12603-009-0204-9.
8
Physiopathological mechanism of sarcopenia.肌肉减少症的生理病理机制。
J Nutr Health Aging. 2009 Oct;13(8):717-23. doi: 10.1007/s12603-009-0203-x.
9
Towards a definition of sarcopenia--results from epidemiologic studies.关于肌肉减少症的定义——流行病学研究结果
J Nutr Health Aging. 2009 Oct;13(8):713-6. doi: 10.1007/s12603-009-0202-y.
10
Epidemiology and consequences of sarcopenia.肌肉减少症的流行病学及后果
J Nutr Health Aging. 2009 Oct;13(8):708-12. doi: 10.1007/s12603-009-0201-z.